Viking Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viking Therapeutics (VKTX).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

1S.Buy

15Buy

2Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$95Upside to Avg. PT+244.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	Joon Lee	Initiate	Buy	$94
Oct 7, 2026	Truist Securities	Joon Lee	PT Cut	Buy	$87→$85
Sep 23, 2026	Truist Securities	Joon Lee	PT Raise	Buy	$83→$87
Aug 11, 2026	JP Morgan	Hardik Parikh	PT Cut	Overweight	$75→$65
Jul 30, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$107→$114
May 28, 2026	Lake Street	Daniel Brims	Initiate	Buy	$89
May 1, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$125
Apr 30, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Cut	Overweight	$105→$100
Mar 23, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Nov 12, 2025	Canaccord Genuity	Edward Nash	PT Raise	Buy	$106→$107
Oct 29, 2025	Canaccord Genuity	Edward Nash	Initiate	Buy	$106
Oct 24, 2025	JP Morgan	Hardik Parikh	PT Cut	Overweight	$80→$75
Oct 23, 2025	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$98→$102
Sep 29, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Sep 22, 2025	BTIG	Justin Zelin	Maintained	Buy	$125
Aug 19, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Jul 24, 2025	Raymond James	Ryan Deschner	PT Cut	Strong Buy	$125→$122
Jul 24, 2025	Citigroup	David Lebowitz	PT Raise	Neutral	$31→$38
Jun 25, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Apr 28, 2025	Cantor Fitzgerald	Steven Seedhouse	Initiate	Overweight	$104

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $83 to $87.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

Lake Street analyst Daniel Brims initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $89.

Benzinga Newsdesk

Viking Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Viking Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

PRO
Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

People Also Watch

People Also Watch

Viking Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Viking Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PROTruist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PROTruist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PROJP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PROCanaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

PROLake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

PRO
Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89